AGE-SPECIFIC CLINICAL PRACTICE GUIDELINES FOR EARLY-ONSET BOWEL CANCER To be developed by Bowel Cancer Australia in collaboration with the Australian Living Evidence Collaboration (ALEC)
With
Dr Prasad Cooray, Medical Oncologist,
Yarra Oncology &
Clinical Researcher & Lecturer,
The University of Melbourne &
Spokesperson, Bowel Cancer Australia
SEGMENT
Filmed in Melbourne | April 2026
Each year almost 1,900 Australians are diagnosed with early-onset bowel cancer (under age 50), and they are currently managed according to clinical practice guidelines that are not age specific.
The National Health and Medical Research Council (NHMRC) has agreed to consider for approval the Clinical Practice Guidelines for the Early Diagnosis and Management of Early-Onset Colorectal Cancer (EOCRC), to be developed by Bowel Cancer Australia in collaboration with the Australian Living Evidence Collaboration (ALEC), and funded by Bowel Cancer Australia. ALEC is led by Cochrane Australia and based in the School of Public Health and Preventive Medicine at Monash University.
“Development of co-designed age-appropriate guidelines is essential given the rising rates of bowel cancer among Australians under 50 to ensure they reflect the unique clinical challenges younger people encounter,” Bowel Cancer Australia CEO Julien Wiggins said.
“The guidelines will use an established ‘living’ approach to generate up-to-date, evidence-based guidance to support clinical decision-making. As soon as new research becomes available, it can be incorporated into the guidelines and translated into clinical practice in near real-time.”
“Young Australians diagnosed with bowel cancer face a very different disease trajectory compared to older patients, yet they are managed under the same clinical framework,” Medical Oncologist and Bowel Cancer Australia spokesperson Dr Prasad Cooray, said to Australian Health Journal.
“That gap has real consequences, contributing to delayed diagnosis, more advanced stage at presentation, poorer survival outcomes, and long-term impacts on fertility, survivorship, and quality of life.
Young women are a particular concern because fertility and pregnancy can be impacted by treatment while postpartum changes can hide or confuse symptoms.
Source: Adapted from Bowel Cancer Australia media release (February 2026)
-
HEALTH CARE BRIEF: Type 1 Diabetes (T1D)
Type 1 Diabetes – Incidence rates, management, lived experience & research
-
National Cancer Plan activates Australian Comprehensive Cancer Network
The landscape of cancer care in Australia is set to transform with the Australian Government launch in May 2024 of the Australian Comprehensive Cancer Network (ACCN) at the Innovations Showcase event, hosted by Cancer Australia in Sydney, Australia.
The ACCN is a nationally integrated system of cancer care, aimed at enhancing patient experiences and outcomes through coordinated and equitable access, by linking to comprehensive cancer services across Australia. Anchored by Comprehensive Cancer Centres (CCCs), the ACCN strives to deliver evidence-driven prevention, diagnosis, treatment, and support to all Australians affected by cancer.
-
The role of genomic screening in transforming public health
Dr Jane Tiller is a lawyer, genetic counsellor and public health researcher. She is Ethical, Legal & Social Adviser in Public Health Genomics at Monash University, and a National Health and Medical Research Council Investigator Grant holder. Jane is passionate about the use of genomics to prevent disease, and in delivering equitable access to preventive genetic information at the population level. She is co-lead of DNA Screen, a world-first study piloting the offer of preventive DNA screening to the Australian adult population. DNA Screen has tested over 10,000 young people for genetic high risk of medically actionable conditions such as cancer and heart disease, finding about 2% of participants had genetic high risk. Jane is leading efforts to secure Commonwealth Government funding to expand the DNA Screen program, with the eventual goal of the development of a public health population screening program for disease prevention based on high genetic risk.
